Japan Customs and research peptides — what the rules say, and why there are no interception rates
Japan Customs checks imported medicines against the PMD Act's import rules (Japan Customs). This article sets out what Japan Customs and MHLW publish about personal imports, and what they do not. PeptideGuide found no official or verifiable statistics on how often research-peptide parcels are stopped by origin country, courier or airport; earlier versions of this page quoted such rates without a source, and they have been withdrawn.
What customs checks: importing medicines as a business is limited to licensed marketing-authorisation holders and manufacturers (Japan Customs). An individual may import medicines for their own use within set quantities after a customs check: one month's supply at the labelled dosage for prescription drugs and poisonous or powerful drugs, 24 standard-size units per item for external-use products, and two months' supply for other medicines (Japan Customs).
Above those quantities: the importer must first obtain an import confirmation certificate (輸入確認証) from a Regional Bureau of Health and Welfare and show it at the import declaration; it replaced Yakkan Shoumei on 1 September 2020. Medicines on MHLW's list of products that could cause serious harm if self-used cannot be imported by individuals in any quantity unless a doctor's prescription can be confirmed.
Penalties: importing a medicine without a confirmation that PMD Act Article 56-2(1) requires is punishable under Article 84 by up to three years' imprisonment, a fine of up to ¥3 million, or both (e-Gov).
Own use only: imported medicines may not be sold or given to anyone else, even free of charge, and other people's portions may not be imported together (MHLW).
Institutions: importing unapproved medicines for testing and research needs import confirmation with a research plan (試験研究計画書) under MHLW's import-confirmation guideline; clinical trials are notified under PMD Act Article 80-2(2).
What PeptideGuide could not find: official statistics on how many research-peptide parcels are stopped; any evidence that customs treats parcels differently by origin country, courier or airport; and how customs handles a held parcel of research peptides. PeptideGuide does not recommend misdescribing goods or concealing them in packaging.
✓Pros
- Japan Customs and MHLW publish the personal-import limits and the documents required
- Institutions have a documented import route: import confirmation with a research plan
- Imports within the personal-use limits need no certificate
×Cons
- No official statistics on how often research-peptide parcels are stopped
- No JP-domestic vendors to bypass customs entirely
- Importing above the limits without a required confirmation is an offence under PMD Act Article 84
- MHLW guidance does not say which quantity category applies to research-labelled peptides
What's the actual interception rate for JP-bound peptide shipments?
PeptideGuide found no official or verifiable figure. Japan Customs and MHLW publish the import rules, not clearance rates for research peptides. Earlier versions of this page quoted community-reported rates without a source; they have been withdrawn.
Does courier choice or origin country matter?
PeptideGuide found no official source showing that customs treats parcels differently by courier or origin country. The same rules apply to every personal import: own use only, within MHLW's quantity limits, with an import confirmation certificate above them (Japan Customs).
What happens if my shipment is intercepted?
Above the personal-use limits, medicines need an import confirmation certificate, which must be shown to customs at the import declaration (Japan Customs). PeptideGuide has no official source on deadlines or on what happens to a held parcel.
Should vendors declare shipments as research chemicals?
PeptideGuide found no official statement on how a research-use-only declaration is treated, and does not recommend misdescribing goods. For imports that need confirmation, MHLW's guideline tells reviewers to check the import purpose in detail.
What about stealth packaging?
PeptideGuide does not recommend it. Concealing goods does not change the import rules: medicines above the personal-use limits need an import confirmation certificate, and importing without a required confirmation is an offence under PMD Act Article 84.
Which airport is the toughest?
PeptideGuide found no official data comparing airports or international mail offices.
More from this region.
Other articles covering this region's vendors, regulatory framework, and research peptides.
- 2026-10-08Earlier versions quoted Japan Customs clearance rates by origin (UK 70–85%, US 50–65%, China 35–55%) as community-reported data, and described differences by courier, airport and declaration, PMDA referral of parcels and customs intelligence priorities. PeptideGuide found no source for any of these and withdrew them; the page now sets out only what Japan Customs, MHLW and the PMD Act publish.
- 2026-10-07Earlier versions named Yakkan Shoumei as a current document and Clinical Trial Notification as the institutional import route, said customs give buyers 30 days to produce it, said the typical outcome for individual buyers is seizure with no follow-up, called escalation under Article 84 rare and described ordering as "expected-value-positive". MHLW replaced Yakkan Shoumei with the import confirmation certificate (輸入確認証) on 1 September 2020, which must be shown to customs at the import declaration; laboratory research imports need import confirmation with a research plan, while Clinical Trial Notification covers clinical trials. PeptideGuide found no official source for the 30-day period or for how often Article 84 is applied; importing without a required confirmation is itself an Article 84 offence. The affected sentences were corrected.